Nautilus Biotechnolgy (NAUT) Stock Statistics & Valuation Metrics

Nautilus Biotechnolgy has a market cap or net worth of $245.03M. The enterprise value is -$28.20M.

Nautilus Biotechnolgy has 126,305,120 shares outstanding. The number of shares has decreased by -2.65% in one year.

Nautilus Biotechnolgy’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -34.06%.

The current PE Ratio of Nautilus Biotechnolgy is ―. Nautilus Biotechnolgy’s PEG ratio is -0.30.

In the last 12 months, Nautilus Biotechnolgy had revenue of 0.00 and earned -70.78M in profits. Earnings per share was -0.56.

In the last 12 months, operating cash flow was -52.63M and capital expenditures -1.29M, giving a free cash flow of -53.92M billion.

Nautilus Biotechnolgy pays an annual dividend of ―, resulting in a dividend yield of ―

Nautilus Biotechnolgy upcoming earnings date is Feb 19, 2026, Before Open (Confirmed).

Nautilus Biotechnolgy as a current ratio of 17.40, with Debt / Equity ratio of 15.96%

In the past 12 months, Nautilus Biotechnolgy has paid 0.00 in taxes.

Nautilus Biotechnolgy EV to EBITDA ratio is -3.31, with an EV/FCF ratio of -3.49.

Nautilus Biotechnolgy has $131.43M in cash and marketable securities with $27.00M in debt, giving a net cash position of $104.42M billion.

Gross margin is 50.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Nautilus Biotechnolgy is $2.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy